louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02152020: Patient-Centered Acupuncture for Pain (PCAP)
Official title: Patient-Centered Integration of Acupuncture to Decrease Pain for Cancer Survivors
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cancer Survivors
Lead sponsor: Abramson Cancer Center at Penn Medicine
Sponsor class: OTHER
First posted: 2014-06-02
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Cancer survivors 18 years or older with pain ratings of 4 or greater on a 0-10 numerical rating scale; primary diagnosis of cancer (stages I-III); finished primary cancer treatment; Karnofsky score 60 or greater; and who have been taking pain medications daily.

Brief summary: The objective of this study is to find out if acupuncture can improve the management of pain in cancer patients when used as part of a treatment plan that includes conventional pain medications. The investigators will enroll 36 cancer patients at Abramson Cancer Center and Penn Cancer Network sites. Participants will be enrolled in either the Conventional Pain Management group or Integrative Pain Management group.


Eligibility criteria: Inclusion Criteria:

* Women or men age 18 years or older
* Primary diagnosis of cancer with history of stage I, II, or III cancer
* Finished primary cancer treatments (surgery, chemotherapy, radiotherapy)
* Have a Karnofsky score of 60 or greater
* Can understand written English
* Have worst pain rated at least 4 or greater on an 11-point (0-10) numerical rating scale in the preceding week
* Have been taking pain medications daily
* Have had at least 15 days with pain in the preceding 30 days.

Exclusion Criteria:

* Women or men with metastatic (stage IV) cancer
* Unstable and progressive medical conditions as judged by the PIs or designated research nurse at the community hospitals (e.g., progressive cancer, uncontrolled heart failure) that may require hospitalization in the next 12 weeks
* Planned surgical procedures in the next 12 weeks
* Patients currently in a pain crisis as judged by the PI or designated research nurse that may warrant acute titration of medications or hospitalization
* Women who are pregnant or breastfeeding
* Unwillingness to adhere to study related procedures.

Primary outcomes:
measure: Number of Adverse Events
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Abramson Cancer Center of the University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: Abramson Cancer Center at Penn Medicine
name: Jun Mao, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06535620: Comparison of the Effect of Red Wine With Alcohol on Flow-mediated Dilation Versus Red Wine Without Alcohol
Official title: Comparison of the Effect of Red Wine With Alcohol on Flow-mediated Dilation Versus Red Wine Without Alcohol - a Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE1
PHASE2
Conditions: Healthy
Healthy Diet
Keywords: wine
cardiovascular disease
Lead sponsor: Instituto de Cardiologia de Santa Catarina
Sponsor class: OTHER
Collaborators: name: Universidade do Sul de Santa Catarina
First posted: 2024-08-02
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Introduction: Cardiovascular diseases (CVDs) are the leading cause of global mortality, despite being preventable. Moderate wine consumption has been associated with one of the preventative approaches due to its benefits on cardiovascular health, including endothelial protection and antioxidant effects, attributed to its chemical composition, such as flavonoids.

Objective: To assess endothelial function through flow-mediated dilation after the consumption of red wine compared to non-alcoholic wine.

Methodology: A parallel, randomized, placebo-controlled clinical trial with a blinded evaluator will be conducted with 20 healthy participants, evaluated at two distinct time points. Participants will be selected to receive either red wine or non-alcoholic wine and will be crossed over after 7 days to receive the opposite beverage from the initial one. The primary outcome will be the change in flow-mediated dilation of the brachial artery pre- and post-intervention in both groups. The secondary outcomes will include the flow-mediated dilation values, brachial artery diameter after the intervention, and measurements of systolic blood pressure (SBP) and diastolic blood pressure (DBP).


Eligibility criteria: Inclusion Criteria:

* consume alcohol sporadically

Exclusion Criteria:

* continuous medication, including anti-inflammatories
* pregnant women

Primary outcomes:
measure: Flow-mediated dilation
timeFrame: 40 minutes after the substance intake
Secondary outcomes:
measure: Heart rate
timeFrame: 40 minutes after the substance intake
measure: Blood pressure
timeFrame: 40 minutes after the substance intake
measure: Brachial artery diameter at rest
timeFrame: 40 minutes after the substance intake
measure: Brachial artery diameter after endothelial stress
timeFrame: 40 minutes after the substance intake
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01525420: Improving Smoking Cessation Quitlines: Pilot Study of Acceptance Therapy
Official title: Improving Smoking Cessation Quitlines: Pilot Study of Acceptance Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Smoking
Lead sponsor: Fred Hutchinson Cancer Center
Sponsor class: OTHER
Collaborators: name: Consumer Wellness Solutions
First posted: 2012-02-03
Enrollment: 121
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to demonstrate that Acceptance Therapy (ACT's) implementation outcomes are at least as good as those of traditional cognitive behavioral therapy (CBT).

Implementation outcomes:

* end of treatment and 6-month follow-up data retention rates;
* intervention implementation quality;
* number \& length of calls completed.

Comparison of each arm's implementation


Eligibility criteria: Inclusion Criteria:

1. aged 18 and older;
2. smokes at least 10 cigarettes daily and has done so for at least the past 12 months;
3. wants to quit smoking in the next 30 days;
4. willing to be randomly assigned to either group;
5. willing and able to speak and read in English;
6. willing and medically eligible to use nicotine replacement therapy (NRT),
7. currently resides in the U.S., and expects to continue for at least 12 months;
8. not participating in other smoking cessation interventions;
9. has regular access to a telephone.
10. has regular access to an email address.

Exclusion Criteria:

* The Exclusion criteria are the opposite of the Inclusion criteria listed above. In addition, the following exclusion criteria also apply:

  1. another member of household enrolled in the study;
  2. currently using medication or nicotine replacement products to help with quitting smoking;
  3. currently using any non-cigarette tobacco products;
  4. pregnant or breastfeeding;
  5. had a heart attack in last 30 days;
  6. within the last 6 months, diagnosed with angina, heart pain, or irregular heartbeat;
  7. serious adverse reactions to nicotine patches including anaphylaxis and related symptoms such as hives, respiratory difficulty, and/or angioedema.

Primary outcomes:
measure: Number of Participants Who Stopped Smoking by 6 Month Post Treatment
timeFrame: 6 months
Secondary outcomes:
measure: 7-day and 24-hour Point Prevalence Quit Rates
timeFrame: 6-month
Other outcomes:
Locations:
city: Seattle
country: United States
facility: Fred Hutchinson Cancer Research Center
state: Washington
Study officials:
References:
citation: Jackson S, Brown J, Norris E, Livingstone-Banks J, Hayes E, Lindson N. Mindfulness for smoking cessation. Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD013696. doi: 10.1002/14651858.CD013696.pub2.
Clinical trial NCT03916120: Single Nucleotide Polymorphisms (SNPs) Associated With Postoperative Analgesic Failure
Official title: Single Nucleotide Polymorphisms (SNPs) Associated With Postoperative Analgesic Failure After Single-port Video-Assisted Thoracoscopic Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pain, Postoperative
Thoracic Surgery, Video-Assisted
Polymorphism, Single Nucleotide
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2019-04-16
Enrollment: 198
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients receiving single-port video-assisted thoracoscopic surgery.

Brief summary: Postoperative pain remains relatively high within 48h for Chinese patients who receive video-assisted thoracoscopic surgery. Different patients experience different pain intensity. This suggests that there may be genetic variants that make some patients susceptible to analgesic failure. Using blood samples from patients, the investigators are going to analyze the relationship between single nucleotide polymorphisms (SNPs) in genes that are known to be involved in analgesic failure.


Eligibility criteria: Inclusion Criteria:

* Age ≤ 70 and Age ≥18
* Selective operation lung section with video-assisted thoracic surgery (VATS)
* III ≥ American Society of Anesthesiologists classification (ASA classification) ≥I
* Patients informed and agreed to join the study

Exclusion Criteria:

* Abnormal function of liver and kidney
* Allergic- dependence history of alcohol, opioids and Local anesthetics
* No noncompliance
* Mental disease history，language communication disorder，cicatricial diathesis
* Underweight or overweight（BMI\<18 or \>30)
* Patients not suitable for clinical subjects for other reasons
* Sedatives, analgesics, antiemetic drugs and anti pruritus drugs were used within 24hours before the operation.
* History of previous abnormal anaesthesia
* Women during pregnancy or lactation

Primary outcomes:
measure: Postoperative analgesic failure
timeFrame: 8 a.m. at the first day after surgery.
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: The second affiliated hospital of Zhejiang University
state: Zhejiang
Study officials:
affiliation: Zhejiang University
name: Min Min, Doctor
role: STUDY_CHAIR
References:
citation: Xing X, Bai Y, Sun K, Yan M. Single nucleotide polymorphisms associated with postoperative inadequate analgesia after single-port VATS in Chinese population. BMC Anesthesiol. 2020 Feb 5;20(1):38. doi: 10.1186/s12871-020-0949-6.
Clinical trial NCT02837120: Retrospective Study of Acute Chest Pain in Extremely Critical Condition for More Than Ten Years
Official title: Retrospective Study of Acute Chest Pain in Extremely Critical Condition for More Than Ten Years
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Myocardial Infarction
Pulmonary Embolism
Aortic Dissection
Keywords: retrospective study
acute myocardial infarction
acute aortic dissection
pulmonary embolism
unstable angina
Lead sponsor: Qilu Hospital of Shandong University
Sponsor class: OTHER
First posted: 2016-07-19
Enrollment: 7000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients admitted in Qilu Hospital with high risk chest pain diseases(acute myocardial infarction, aortic dissection, pulmonary embolism, unstable angina) from 2003.01 to 2015.09

Brief summary: Acute non-traumatic chest pain is a common kind of symptom in extremely critical condition, with various pathogenesis and different level of risk . Chest pain in high risk takes 1/3 of that. It mainly includes acute coronary syndrome (including myocardial infarction and unstable angina pectoris, accounted for over 95% of chest pain in high risk), aortic dissection, pulmonary embolism etc, and is in high lethality and deformity.

The investigators do the research :

1. To study the diagnosis and management condition of acute chest pain in extremely critical condition for last ten or more years in Qilu Hospital,Shandong University.
2. To discuss the significance of key accompanying symptoms(for example radiating pain, chest distress, sweating, nausea etc), physical signs and lab examination in early diagnosis and risk stratification of acute chest pain in extremely critical condition.
3. To study the effect factors of thrombus burden in STEMI patients, at the same time, creat a a simple, practical and scientific method of blood clots classification.


Eligibility criteria: Inclusion Criteria:

* Inpatients of Qilu Hospital, whose electronic medical records were searched out by terms of acute myocardial infarction, aortic dissection, pulmonary embolism and unstable angina in International Classification of Diseases(ICD)-10 code from Jan.2003 to Sep.2015.

Exclusion Criteria:

* Patients whose medical records are false, omitted or uncompleted because of transference, death et al.

Primary outcomes:
measure: Diagnosis and management of acute chest pain diseases in extremely critical condition
timeFrame: A week after data collected
Secondary outcomes:
measure: Clinical characteristics of participants for demographics, medical history, examination results and investigations retrieved from electronic medical records
timeFrame: A week after data collected
measure: The predicted factors of thrombus burden in STEMI patients, and the influence of thrombus burden on mortality
timeFrame: A week after data collected
Other outcomes:
Locations:
city: Jinan
country: China
facility: Qilu Hospital of Shandong University
state: Shandong
Study officials:
References:
Clinical trial NCT00748020: Narrow-Band UVB-Therapy in Psoriasis
Official title: Narrow-Band UVB-Therapy in Psoriasis: Randomised Double-Blind Comparison of Erythematogenic and Suberythematogenic Irradiation Regimens
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Psoriasis
Lead sponsor: Radboud University Medical Center
Sponsor class: OTHER
First posted: 2008-09-08
Enrollment: 109
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Study on two different irradiation schemes in UVB phototherapy for psoriasis. Previous studies demonstrated a similar clinical effect in erythematogenic and suberythematogenic irradiation, with less complications in suberythematogenic irradiation. Most of these studies used both irradiation schemes within the same patient. UVB has a systemic effect on the body. Our hypothesis is that previous conclusions are incorrect and that the erythematogenic scheme will result in earlier clearance of the psoriasis.

Detailed description: 109 psoriasis patients, referred for UVB phototherapy, participated in our study after given their written informed consent. After determining the minimal erythema dose (MED) patients were randomised in either group 1, erythematogenic scheme, or group 2, suberythematogenic scheme. Group 1 started with 70% of MED and every following irradiation with an increase of 40%. Group 2 started with 30% of MED and every next visit an increase of 20%. The study protocol was adjusted in case of erythema (sunburn) according to a standard erythema-phototherapy protocol, varying from skip one irradiation to lowering the percentage of increase. In case of clearance the study stopped. Clearance was defined as less than 10% of baseline body area of psoriasis.

Eligibility criteria: Inclusion Criteria:

* Eligible for UVB phototherapy
* Older than 18 years

Exclusion Criteria:

* No topical medication for 2 weeks
* No systemic medication for 4 weeks
* No medication (betablocker, lithium) interfering with psoriasis

Primary outcomes:
measure: clearance is defined as less than 10% affected body area with psoriasis compared with baseline
timeFrame: every 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Nijmegen
country: Netherlands
facility: Radboud University Nijmegen Medical Centre, Department of Dermatology
Study officials:
affiliation: Radboud University Medical Center
name: Rianne Gerritsen, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04414020: Cytoprotective Effect and Clinical Outcome of Perioperative Proesterone in Brain Tumors
Official title: Cytoprotective Effect and Clinical Outcome of Perioperative Proesterone in Brain Tumors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Diffuse Traumatic Cerebral Edema
Keywords: Progesterone
brain tumor
Neuronal biopsy
Lead sponsor: Minia University
Sponsor class: OTHER
First posted: 2020-06-04
Enrollment: 26
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Neuronal injury is evident in elective craniotomy for space occupying lesions. Surgical trauma and mechanichal impact of the tumor causes neuronal injury. Neurosreroid progesterone is a neurotransmittern , trail to use in abolishing neurotoxcicty

Detailed description: Progesterone is a natural neurosteroid that we are trying to use to impede both direct neuronal injury cauesd by and indirectly by surgical trauma. Progesterone can decreas vasogenic brain oedema. Our primary outcome is to ameliorate microscopic cytoplasmic injury and decrease brain oedema exploited by biopsy from brain tumor interface. Exclusion criteria demonstratd as refusal to participate in the trial , emergency craniotomy, recurrent brain tumor.

Eligibility criteria: Inclusion Criteria:

* All elective brain tumors elligible for craniotomy

Exclusion Criteria:

* Refusal to participare
* Emergency craniotomy

Primary outcomes:
measure: Number of Participants With craniotomy-Related Adverse Events
timeFrame: 3 months
Secondary outcomes:
measure: Number of Participants with neuronal deficit
timeFrame: 2 months
Other outcomes:
Locations:
city: Al Minyā
country: Egypt
facility: Faculty of Medicine
state: Abohelal
city: Minya
country: Egypt
facility: Faculty of Medicine
state: Abohelal
Study officials:
References:
Clinical trial NCT03731520: Determination of Exercise Behavior in Patients With Juvenile Idiopathic Arthritis
Official title: Determination of Exercise Behavior in Patients With Juvenile Idiopathic Arthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Juvenile Idiopathic Arthritis
Keywords: Juvenile Idiopathic Arthritis
exercise
behavior
Lead sponsor: Istanbul University
Sponsor class: OTHER
First posted: 2018-11-06
Enrollment: 100
Sex: ALL
Minimum age (years): 6
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Juvenile idiopathic arthritis (JIA) is one of the most common rheumatic diseases in childhood, affecting at least 1 in 1000 children. Children with JIA experience joint inflammation and swelling, pain and tenderness, morning stiffness, limited mobility. Children with JIA complain pain and have lower functional ability and decreased quality of life compared with their peers. Many studies have reported that patients with JIA have low physical activity levels and also exercise therapy is considered an important component of the treatment of JIA. Nowadays, studies for evaluating exercise behaviours in order to cope with physical inactivity for many chronic diseases are becoming increasingly important.The objective of this study is to determine exercise behaviour in patients with JIA.


Eligibility criteria: Inclusion Criteria:

* Diagnosed as JIA according to ILAR classification
* Aged between 6-18
* Adequate cognitive function for understanding questions

Exclusion Criteria:

- a parent who does not have a smartphone

Primary outcomes:
measure: 11-point Numeric Analogue Scale
timeFrame: baseline
measure: Exercise Stages of Change Scale-Short Form
timeFrame: baseline
measure: Exercise Self-Efficacy Scale
timeFrame: baseline
measure: Decisional Balance Scale
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
city: İstanbul
country: Turkey
facility: Istanbul University-Cerrahpasa
Study officials:
References:
Clinical trial NCT01845220: Prevention of Alcohol Intolerance
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Alcohol Sensitivity
Keywords: Broccoli sprouts
alcohol sensitivity
sulforaphane
alcohol metabolism
in the Asian Community
Lead sponsor: Johns Hopkins University
Sponsor class: OTHER
First posted: 2013-05-03
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This study is designed to determine whether Asians who are especially sensitive to alcohol exposure can be protected by boosting their activities of an alcohol disposing enzyme. This will be accomplished by administering broccoli sprouts that are rich in an agent that increases protective enzyme activity. The test system involves applying alcohol patches to the skin and measuring skin redness.


Eligibility criteria: Inclusion Criteria:

* 18-70 years old,
* sensitive to alcohol on the skin, Japanese

Exclusion Criteria:

* recent skin abnormalities /tanning

Primary outcomes:
measure: Mean Area of Skin Erythema (Skin Redness)
timeFrame: mean up to 2 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins University
state: Maryland
Study officials:
References:
Clinical trial NCT01310920: The Role of Angiotensinogen Gene Polymorphism in the Pathogenesis of Non-familial Sick Sinus Syndrome
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Sick Sinus Syndrome
Lead sponsor: China Medical University Hospital
Sponsor class: OTHER
First posted: 2011-03-09
Enrollment: 400
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Sampling method: PROBABILITY_SAMPLE
Study population: The case group includes 200 patients and the control group includes 200 patients.

Brief summary: Evidence has been documented for the close relationship between the arrhythmia pathogenesis and the gene expression in renin-angiotensin system. However, it remains unclear for involvement of RAS in the pathogenesis of non-familial sick sinus syndrome. The researchers thus investigated the possible relationship between non-familial sick sinus syndrome and the polymorphism and haplotype of the AGT promoter.


Eligibility criteria: Inclusion Criteria:

* sick sinus syndrome

Exclusion Criteria:

* 1.Severe systemic disease.
* 2.Acute coronary syndrome.
* 3.bradycardia with reversible cause.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taiwan
country: Taiwan
facility: China Medical University Hospital
Study officials:
affiliation: China Medical University Hospital
name: Jan-Yow Chen, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mangrum JM, DiMarco JP. The evaluation and management of bradycardia. N Engl J Med. 2000 Mar 9;342(10):703-9. doi: 10.1056/NEJM200003093421006. No abstract available.